Identifying Predominant Causes of Death Among Hospitalized COVID-19 Patients During Poland\'s Second and Third Waves DOI Creative Commons

Irina Niecwietajewa,

Michał Frączek,

Maria Mroczkowska

et al.

Medical Science Monitor, Journal Year: 2023, Volume and Issue: 29

Published: Sept. 12, 2023

BACKGROUND Number of confirmed COVID-19 deaths per million population in Poland between November 2020 and May 2021 was one the largest Europe. This retrospective study conducted at a single center 2021to evaluate morbidity mortality rates 581 patients hospitalized with COVID-19. MATERIAL AND METHODS A single-center dedicated hospital from November, to May, 2021. The data were analyzed. Multimorbidity assessed using Charlson Comorbidity Index, including chronic kidney, respiratory, cardiovascular diseases, diabetes mellitus, cancer, dementia. observation period covered admission for severe until discharge or death. Diagnosis by quantitative reverse transcription polymerase chain reaction test. Statistical analysis carried out IBM SPSS Statistics program. RESULTS rate 35% all admitted patients. Lung damage cause death 60%, bacterial superinfection 26%, arterial thrombosis thromboembolism 9%, heart failure 5% chi-square test showed significant relationship sex related pneumonia ventilator-associated (VAP). CONCLUSIONS findings this supports other countries that 2021, before SARS-CoV-2 vaccination programs fully implemented effective medications antiviral agents developed, had high mortality.

Language: Английский

Emerging anti-spike monoclonal antibodies against SARS-CoV-2 DOI
Eloy E. Ordaya, Raymund R. Razonable

Expert Opinion on Biological Therapy, Journal Year: 2024, Volume and Issue: 24(3), P. 191 - 201

Published: March 3, 2024

Introduction Anti-spike monoclonal antibodies (mAbs) were previously authorized for the prevention and treatment of COVID-19 in immunocompromised patients. However, they are no longer U.S. due to their lack neutralizing activity against current circulating SARS-CoV-2 Omicron variants.

Language: Английский

Citations

5
SARS-CoV-2 and COVID-19: From Crisis to Solution DOI Open Access
Špela Šalamon, Andrew G. Ewing, Greta Fox

et al.

Published: Jan. 18, 2024

Author Affiliations: World Health Network Corresponding author: Spela, Salamon, [email protected] Abstract The global impact of the COVID-19 pandemic persists, causing significant harm. Extensive evidence indicates that even mild infections and reinfections can result in symptomatic subclinical health damage, disability, persistent infection. Vascular impacts, neurotropism, immune dysregulation lead to impaired organ function, increased … Continued

Language: Английский

Citations

2
Acromegaly and COVID-19, lessons, and new opportunities DOI
Elena V. Varlamov, Maria Fleseriu

Pituitary, Journal Year: 2024, Volume and Issue: 27(6), P. 935 - 944

Published: May 31, 2024

Language: Английский

Citations

1
Specific humoral immune response and XBB variants re-infection risk of hemodialysis patients after Omicron BA.5 infection in China DOI

Weikang Mai,

Jinwei Shen,

Feifei Ma

et al.

Vaccine, Journal Year: 2024, Volume and Issue: 42(21), P. 126108 - 126108

Published: July 24, 2024

Language: Английский

Citations

1
Burden of Acute Respiratory Infections Caused by Influenza Virus, Respiratory Syncytial Virus, and SARS-CoV-2 with Consideration of Older Adults: A Narrative Review DOI Creative Commons
William P. Hanage,

William Schaffner

Infectious Diseases and Therapy, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 30, 2024

Influenza virus, respiratory syncytial virus (RSV), and severe acute syndrome coronavirus 2 (SARS-CoV-2) are infections (ARIs) that can cause substantial morbidity mortality among at-risk individuals, including older adults. In this narrative review, we summarize themes identified in the literature regarding epidemiology, seasonality, immunity after infection, clinical presentation, transmission for these ARIs, along with impact of COVID-19 pandemic on seasonal patterns influenza RSV infections, consideration data specific to adults when available. As adult population increases globally, it is paramount importance fully characterize true disease burden ARIs order develop appropriate mitigation strategies minimize their vulnerable populations. Challenges associated characterizing diseases include shared symptomology presentation RSV, SARS-CoV-2, which complicate accurate diagnosis highlight need improved testing surveillance practices. To end, multiple regional, national, global virologic systems have been established provide knowledge viral support preparedness response potential outbreaks, help inform prevention reduce severity transmission. Beyond illness, long-term health consequences also result from SARS-CoV-2 infection. These cardiovascular pulmonary complications, worsening existing chronic conditions, increased frailty, reduced life expectancy. place a financial society healthcare systems. Collectively, indicate present challenge, underscoring interventions improve outcomes illnesses.Graphical abstract video available article.

Language: Английский

Citations

1
Immunocompromised patients and COVID-19: how do we protect those most at risk? DOI Creative Commons
Jochen Schneider, Johanna Erber,

Lutz Renders

et al.

Expert Review of Anti-infective Therapy, Journal Year: 2023, Volume and Issue: 22(1-3), P. 1 - 3

Published: Dec. 15, 2023

Language: Английский

Citations

3
Effectiveness of COVID-19 vaccines against severe outcomes in cancer patients: Real-world evidence from self-controlled risk interval and retrospective cohort studies DOI Creative Commons

Hui-Eon Lee,

Na‐Young Jeong, Eun‐Cheol Park

et al.

Journal of Infection and Public Health, Journal Year: 2024, Volume and Issue: 17(5), P. 854 - 861

Published: March 15, 2024

The effectiveness of COVID-19 vaccines is generally reduced in cancer patients compared to the general population. However, there are only a few studies that compare relative risk breakthrough infections and severe outcomes fully vaccinated versus their unvaccinated counterparts. To assess patients, we employed (1) self-controlled interval (SCRI) design, (2) retrospective matched cohort design. A SCRI design was used infection during period immediately following vaccination ("control window") which immunity achieved ("exposure windows"). between patients. For both studies, data were extracted from Korea Disease Control Prevention Agency-COVID-19-National Health Insurance Service cohort, including demographics, medical history, records all individuals confirmed with COVID-19. We conditional Poisson regression calculate incidence rate ratio (IRR) for Cox estimate hazard (HR) outcomes. Of 14,448 diagnosed October 2020 December 2021, total 217 3996 included study respectively. While infections, measured by control exposure windows, did not show statistically significant difference (IRR=0.88, 95% CI: 0.64-1.22), significantly lower those (HR=0.27, 0.22-0.34). reduce though efficacy against less evident.

Language: Английский

Citations

0
Effects of Infliximab on patients with COVID-19: a systematic review and meta-analysis DOI Open Access

A Ataei,

Amirhossein Orandi, Ebadallah Shiri Malekabad

et al.

Authorea (Authorea), Journal Year: 2024, Volume and Issue: unknown

Published: April 6, 2024

Despite the control of COVID-19 pandemic, it remains one main concerns healthcare systems throughout world. Inflammation and hyper-reactive immune system play an essential role in developing SARS-CoV-2 infection, particularly immunocompromised patients. Infliximab, anti-TNFα antibody that is used autoimmune disorders, may exert important alleviating inflammation immunity. In this systematic review meta-analysis, we have concluded Infliximab can significantly decrease mortality rate patients with COVID-19. Conversely, did not a significant effect on hospitalization, mechanical ventilation, adverse events during infection. More studies influence are warranted.

Language: Английский

Citations

0
An exploration of the connection between COVID-19 and cardiovascular disease (CVD) in European countries DOI Creative Commons
Niloufar Pourshir Sefidi, Peter Mooney

Journal of Public Health, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 21, 2024

Abstract Aim This study aims to extend the research on connection between COVID-19 and cardiovascular disease (CVD) by exploring this link at a macro level across continent of Europe. We aim highlight virus’s detrimental effects heart health both country continental levels. Subject methods Utilizing data from SHARE survey, we investigated impacts individuals aged 50 over in 26 European countries. A Bayesian hierarchical logistic regression (BHLR) model was employed assess country-level continent-level effects, enabling us account for geographical variations estimate overall impact. Results Our findings indicate 20% average increase CVD risk post-COVID-19 infection, associated with other factors such as hypertension, diabetes, chronic lung disease, elevated BMI. Hypertension particularly notable significant factor. Conclusions provides comprehensive overview how interacts risks It reveals variability impact different countries compared effect observed level. These insights contribute broader understanding COVID-19’s implications public policy individual management context health.

Language: Английский

Citations

0
Impact of oral early antiviral therapies for mild–moderate COVID-19 in the outpatient’s setting during Omicron era: a pharmacoeconomic analysis DOI Creative Commons
Vincenzo Scaglione,

Samuele Gardin,

Lolita Sasset

et al.

European journal of medical research, Journal Year: 2024, Volume and Issue: 29(1)

Published: Dec. 19, 2024

Molnupiravir (MOL) and nirmatrelvir/ritonavir (NIR) decreased mortality hospital admissions in high-risk patients with mild to moderate COVID-19. Nevertheless, there is a lack of data about the pharmacoeconomic impact these antivirals Omicron era. We conducted analysis assessing medical costs use compared those occurred people who refused treatment. The study included first 50 vaccinated against SARS-CoV-2 each month experienced COVID-19 were consecutively treated oral at Padua University Hospital between February 1, 2022, June 30, 2022. In addition, all consecutive met criteria for antiviral therapy during this period but opted not receive treatment as control group. two groups terms associated emergency department visits hospitalizations, which identified primary outcomes study. Nine-hundred-sixty-one analysed, mean age was 67.72 ± 15.19 years 49% males. most prevalent comorbidities cardiovascular disease (57%), obesity (18) diabetes mellitus (18%). Two-hundred-fifty-one (26%) MOL (group A), 252/961 NIR B) 458/961 (48%) C). While generally more favourable observed early group, no statistically significance differences hospitalization or found group A C B C. Total direct significantly higher both comparing (671.42 460€) vs. (1008.42 1562€) (446.58 4977€). main cost driver increased therapy. average 19,334.3 27,030€ C, 8956.2 7412€ 10,267.2€ A. context variant pandemic, agents individuals be expensive avoid treatment, primarily due high it. To enhance efficiency resource allocation, it essential pursue policies aimed reducing drug costs, along conducting further pharmaco-economic studies.

Language: Английский

Citations

0